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Abstract
Objective: This study assessed the efficacy of a closed-loop (CL) system consisting of a predictive rule-based algorithm
(pRBA) on achieving nocturnal and postprandial normoglycemia in patients with type 1 diabetes mellitus (T1DM). The
algorithm is personalized for each patient’s data using two different strategies to control nocturnal and postprandial periods.
Research Design and Methods:We performed a randomized crossover clinical study in which 10 T1DM patients treated with
continuous subcutaneous insulin infusion (CSII) spent two nonconsecutive nights in the research facility: one with their usual
CSII pattern (open-loop [OL]) and one controlled by the pRBA (CL). The CL period lasted from 10 p.m. to 10 a.m., including
overnight control, and control of breakfast. Venous samples for blood glucose (BG) measurement were collected every
20min.
Results: Time spent in normoglycemia (BG, 3.9–8.0mmol/L) during the nocturnal period (12 a.m.–8 a.m.), expressed as
median (interquartile range), increased from 66.6% (8.3–75%) with OL to 95.8% (73–100%) using the CL algorithm (P < 0.05).
Median time in hypoglycemia (BG, <3.9mmol/L) was reduced from 4.2% (0–21%) in the OL night to 0.0% (0.0–0.0%) in the
CL night (P < 0.05). Nine hypoglycemic events (<3.9mmol/L) were recorded with OL compared with one using CL. The
postprandial glycemic excursion was not lower when the CL system was used in comparison with conventional preprandial
bolus: time in target (3.9–10.0mmol/L) 58.3% (29.1–87.5%) versus 50.0% (50–100%).
Conclusions: A highly precise personalized pRBA obtains nocturnal normoglycemia, without significant hypoglycemia, in
T1DM patients. There appears to be no clear benefit of CL over prandial bolus on the postprandial glycemia.
Introduction
Type 1 diabetes mellitus (T1DM) implies a life-threatening absolute insulin deficiency. Since the 1920s
substitution of the hormone using the subcutaneous route has
allowed for the disappearance of ketosis and acute symptoms
of hyperglycemia and, in recent decades, has led to a signif-
icant reduction in the risk of onset and progression of the
long-term microvascular complications thanks to intensified
insulin treatments.1 However, many imperfections of this
treatment, such as risk of severe hypoglycemia,2 constitute a
barrier to achieving an optimal blood glucose (BG) control in
most patients, even when a continuous subcutaneous insulin
infusion (CSII) system is used. Some biological solutions for
T1DM, such as immunomodulation at disease onset or islet
transplantation, are promising, but, unfortunately, the results
they yield are still too poor for near-future clinical appli-
cation.3 Another way of improving current therapies is the
integration of real-time continuous glucose monitoring
(CGM), a technique that has been refined in recent years,4 and
the CSII system, which executes the optimal insulin dose
proposed by a computerized controller, implementing an
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artificial pancreas or artificial b-cell. Closed-loop (CL) is a
specific control engineering term that has also been widely
used to describe the integration of these technologies for
glucose control. Using the same terminology, open-loop (OL)
refers to scenarios where conventional CSII therapy is used.
When using the subcutaneous route, for both measure-
ment and insulin administration, CL strategies have to fight
against well-identified difficulties, the most challenging
probably being the delay in rapid glucose change detection
and the lengthy time needed for subcutaneously administered
insulin to act.5
The most widely used strategies for CL controllers have
been focused on proportional integral derivative control6,7
and model predictive control.8,9 Other approaches use an in-
verse controller10 or imitate the lines of reasoning of diabetes
caregivers, using methods such as fuzzy logic control11 or
rule-based algorithms.12
In the last few years, some clinical experience with CL
control algorithms has yielded favorable results in regulating
BG levels in subjects with T1DM, both in-clinic6–9,13 or very
closely supervised conditions.11 The percentage of time in BG
target range was generally defined as the main goal. For
studies including postprandial periods, although many of
them included postprandial time in their overall results, better
outcomes were obtained in those studies in which a pre-
prandial manual bolus was used.14 Studies focusing on noc-
turnal periods have achieved better results: the percentage of
time ranging from 3.9 to 8.0mmol/L varied roughly from 70%
to 80%.8,9 In the light of these results, it seems reasonable to
assume that nocturnal control will become the first step to-
ward CL strategy implementation in real life.
Our group has developed a glucose controller using a
predictive rule-based algorithm (pRBA) that takes into ac-
count the instant value of glucose indicated by CGM, the
predicted rate of change (pROC), and the nominal basal in-
sulin. In order to assess the efficacy of the pRBA, measured as
time spent in BG target values (3.9–8.0mmol/L), and safety,
measured as the incidence of hypoglycemic events, we per-
formed a crossover clinical trial comparing an OL night, using
CSII therapy, with a CL night.
Research Design and Methods
The pRBA system
The pRBA has been designed following the control-
to-range concept15,16 and complemented by a safety control
module to prevent insulin overdose, similar to other safety
systems.10,17 The pRBA is a hybrid system that requires a
partial premeal insulin administration after considering the
amount of carbohydrates of each meal intake. The algorithm
uses two different strategies to control basal or postmeal pe-
riods, with the mealtime being the reference for switching
between them.
The algorithm is personalized for each patient using the
subject’s adjusted nominal insulin, personal parameters,
such as the correction factor or the insulin-to-carbohydrates
ratio, and some physical characteristics, such as the patient’s
weight. Information for personalizing the pRBA is extracted
from the insulin treatment and data recorded in the patient’s
daily logbook with regard to BG levels, food intake, and other
significant events. The pRBA requires no specific subject
model, and it uses rules with explicit knowledge.
The control-to-range module operates according to the
current glucose value and the pROC calculated with a glucose
predictor based on an artificial neural network.18 The pre-
dictor is trained with CGM dataset sensor files and takes into
account inter- and intrapatient variability. The time horizon
for glucose prediction is 30min.
The goal of the control-to-range module is to achieve glu-
cose values between 4.4mmol/L and 7.8mmol/L and to as-
sure glucose stability, defined as pROC within –0.28mmol/
(L$min) (5mg/[dL$min]). The pRBA control-to-rangemodule
provides as output a parameter n, which is applied to the
nominal basal insulin of each patient and, when required, a
correction bolus.
The control-to-range module is complemented by a safety
control module that modifies the final proposed insulin de-
livery based on the insulin on board, which takes into account
both the insulin pharmacodynamics and the CSII system
constraints. The safety control rules limit the maximum in-
sulin infusion and suspend the insulin delivery at a sensor
glucose level lower than 4.4mmol/L unless the pROC indi-
cates a clear increasing trend (pROC >0.28mmol/[L$min])
or when, despite glucose values being within the desired
range, the pROC indicates a highly fast-decreasing trend
(pROC < –0.84mmol/[L$min]). The time for insulin infusion
suspension is limited to 2 h, but a microbolus of the least
possible insulin dose is administered every 30min after sus-
pension to avoid catheter occlusions.
The final pRBA output is calculated by combining the
control-to-range and the safety control modules, thereby ob-
taining an insulin micro-dose at each time step (every 5min).
The pRBA was evaluated in silico before the clinical study
to test its performance in different conditions. The patient
population was simulated10 using the compartmental model
defined previously.19
Clinical study
Ten adults with T1DM previously treated with CSII were
enrolled in this randomized crossover study. Inclusion criteria
were minimum age of 18 years, diabetes duration longer than
3 years, and CSII treatment for more than 1 year. Exclusion
criteria were hemoglobin A1c of >10% (86mmol/mol) and
concomitant diseases or treatments with drugs that poten-
tially affect glucose control. The entire study was performed
at the Diabetes Day Care Center, Parc Taulı´ Sabadell Uni-
versity Hospital, Barcelona, Spain, and was approved by the
local ethics board (http://www.tauli.cat/tauli/en/docencia/
recerca/recerca.htm). A written informed consent was ob-
tained from all patients.
Patients spent two nonconsecutive nights in the hospital:
one night with their usual CSII therapy (OL night) and one
night controlled by the pRBA (CL night). The order of
participation was determined by randomization. Two pa-
tients, one for each treatment option, were involved on each
night. The CL period lasted from 10 p.m. to 10 a.m., in-
cluding overnight control and control of breakfast, given at
8 a.m.
On the CL night, each patient was equippedwith two CGM
devices (Paradigm REAL-Time; Medtronic, Minneapolis,
MN) beginning at least 24 h before admission. CGM devices
were calibrated at home using the patient’s glucose meter
according to the manufacturer’s recommendations.
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Patients arrived at the hospital at 6 p.m. Then, one sensor
was chosen as the reference measurement for the experiment
based on its reliability and accuracy, whereas the second one
was kept as backup to be used in case of reference sensor
failure. On patient admission, the CGM devices were cali-
brated using an YSI STAT Plus 2300 glucose and lactate
analyzer (YSI, Yellow Springs, OH). Dinner (Mediterranean
salad, roast chicken, fries, bread, and fruit) and breakfast
(white coffee, bread, ham, and cheese) meals were identical on
both nights, and their composition was calculated according
to each patient’s habits. An intravenous cannula was inserted
into each patient’s antecubital vein. Blood samples were col-
lected every 20min for reference glucose measurement. Hy-
poglycemia was defined as a YSI reading of <3.9mmol/L
with or without symptoms recognized by the patient as re-
lating to hypoglycemia and was treated with 5–20 g of car-
bohydrate (orange juice).
At 10 p.m. the patient’s CSII was switched to an Animas
2020 (Animas Corp., West Chester, PA), chosen because it
allows the fastest bolus delivery. The insulin pump was pre-
viously filled with insulin analog aspart (Novorapid; Novo
Nordisk, Copenhagen, Denmark). The insulin basal infusion
was set to zero when the CL period started. pRBA was ini-
tialized with each patient’s data (CGM glucose, carbohydrate
intake, and delivered insulin) recorded during the 10-h period
preceding the start of the CL delivery.
The sensor reading, pump operation, and the algorithm-
running were donemanually by two different members of the
team located in different rooms. As the algorithm was exe-
cuted very frequently, only one person stayed in the room
with the patient in order to avoid disturbing him or her during
the night. An ad hoc local area network, not connected to the
Internet, was configured to allow the researchers to commu-
nicate through videoconference software, including a chat
message service. Three computers were connected to the
network at the following sites: the patient’s room, the algo-
rithm area, and the YSI. An alarm clock software producing
light and sound alarms was running and synchronized with
all three computers. From 12 midnight to 7 a.m., the sound
alarms were switched off.
The process was as follows: every 5min, 30 and 10 s before
the scheduled time, the alarm clock activated an alarm, and
the physician seated close to the patient read the sensor
monitors (reference and backup) and wrote the two glucose
values into the chat. In the algorithm area, a technician en-
tered the reference sensor glucose value into the algorithm,
which then calculated the new insulin microbolus. The tech-
nician wrote the insulin dose proposed by the algorithm into
the chat, and the patient-side physician operated the pump to
deliver the insulin. The whole process took around 30 s. Every
20min, YSI values were also sent by chat from the YSI-side
computer. This procedure was maintained for 12 h. To facili-
tate controller supervision, all the information was available
to all the researchers in real time both as numerical data and as
graphs. The research team comprised two research nurses,
three physicians, and three technicians.
At 7:45 a.m. a priming bolus of 50% of the usual bolus was
given, and at 8 a.m. breakfast was served. The rest of the
prandial insulin was administered by pRBA as required by
the evolution of CGM values. At 10 a.m. the experiment fin-
ished, and patients returned to their usual CSII with the usual
basal profile.
For the OL night, a single CGM sensor was inserted for at
least 24 h before admission with data being available for the
patient. Patients arrived at the research facility at 6 p.m., and,
as on the CL night, dinner was served at 8 p.m., breakfast was
served at 8 a.m., and patients stayed in the hospital until 10
a.m.However, on the OL night they used a sensor-augmented
pumpwith their usual basal rates and bolus during the whole
study period. Blood samples were collected, as on the CL
night, for venous glucose measurement, every 40min from 12
a.m. to 8 a.m. and every 20min for the rest of the period.
Statistics
The statistical analysis plan was designed in advance. The
primary outcome was time spent in normoglycemia (3.9–
8.0mmol/L) during the overnight period (12 a.m.–8 a.m.).
Secondary outcomes were percentage of time and number
of episodes of hypoglycemia (BG level, <3.9mmol/L) and
variability parameters (interquartile range, SD, Low BG
Index, High BG Index, and BG Risk Index).20 All the results
are expressed as mean – SD or median (interquartile range)
values. For calculating percentiles, Tukey’s method was used.
Statistical comparison between OL and CL was done using
the nonparametric test for paired samples (Wilcoxon test).
Analyses were carried out with SPSS version 20 software
(IBM, Armonk, NY).
Results
All 10 patients (five women; mean– SD age, 46.7 – 10.82
years old; mean– SD diabetes duration, 18.0 – 5.7 years;
mean– SD body mass index, 25.7 – 3.2 kg/m2; mean– SD he-
moglobin A1c, 7.1 – 0.8% [55 – 8.7mmol/mol]) completed the
study. Carbohydrate content of the dinner was 57.0 – 16.3 g,
and that of the breakfast was 41.0 – 12 g. All the insulin doses
proposed by the algorithm were checked by an endocrinolo-
gist and actually administered. Individual characteristics of
the patients are shown in Table 1.
Accuracy of CGM
The sensors chosen for the CL part of the study showed an
acceptable accuracy (median absolute relative difference,
12.6% [4.8–26.5%]). Clarke error grid analysis21 showed 79.4%
in Zone A, 18.7% in Zone B, and 1.8% in Zone D. Continuous
error grid analysis22 showed 81.4% of values in Zone A
for both rate and point-error grid analysis regarding eu-
glycemia. However, this percentage decreased to 22.2% for
hypoglycemia ( £ 3.9mmol/L) and 58.6% for hyperglycemia
(> 10mmol/L). The second sensor was not used to run the
algorithm at any time. Occasionally, there were very short
periods of reference sensor signal loss, but these were always
shorter than 10min. On these occasions the previous reference
sensor value was used.
Overnight period
From starting CL to breakfast (10 p.m.–8 a.m.). Starting
BG level was similar in the OL and CL sessions (8.9 – 4.1 vs.
8.7 – 5.1mmol/L). No statistical differences were found in the
overnight mean BG between OL and CL nights (7.8 – 2.3 vs.
6.8 – 1.9mmol/L), although the range of BG was tighter (5.4–
12.3mmol/L for OL nights vs. 4.9–10.6mmol/l for CL nights)
(Fig. 1). Percentage of time in normoglycemia (3.9–8mmol/L)
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was lower duringOL versus CL (median [interquartile range],
60.0% [17–69%] vs. 93.3% [70–99%], respectively; P < 0.05)
(Fig. 2). Control variability grid analysis23 showed eight pa-
tients in Zones A +B for CL but only four patients for OL
nights.
From midnight to 8 a.m. No difference in mean BG
level was found between OL and CL nights (7.29 – 2.5 vs.
6.4 – 1.6mmol/L; difference not significant). Percentage of
time in target was clearly higher for CL nights (OL vs. CL,
66.6% [8.3–75%] vs. 95.8% [73–100%]; P< 0.05). Nine hypo-
glycemic events were recorded using OL, but only one epi-
sode ( = 3.3mmol/L) was observed using CL. Percentage of
time with BG values < 3.9mmol/L was 4.2% (0–21%) for OL
but 0.0% (0–0%) for CL (P < 0.05).
Glucose stability (12 a.m.–8 a.m.). The SD tended to
decrease with CL (from 1.48– 0.67mmol/L to 0.92–
0.44mmol/L; P= 0.08). After 10h of pRBA action a conver-
gence between all subjects in a near-normoglycemic point was
observed (OL vs. CL: 10 p.m., 8.0 [3.97] vs. CL 7.2 [2.86] mmol/
L; 8 a.m., 6.03 [2.05] vs. 5.22 [1.05] mmol/L) (Fig. 1).
Table 1. Individual Data of All Patients
Subject identification
Total/
mean – SD 1 2 3 4 5 6 7 8 9 10
Sex (M/F) 5/5 F F M M M M M F F F
Age (years) 46.7 – 10.8 64 35 59 39 43 58 51 39 46 33
Height (m) 1.7 – 0.1 1.64 1.60 1.65 1.81 1.90 1.70 1.69 1.64 1.66 1.67
Weight (kg) 74.5 – 15.1 64.4 64.9 75.7 75 110.6 65.9 89.3 64.4 62 72.6
BMI (kg/m2) 25.7 – 3.2 23.9 25.3 27.8 22.9 30.6 22.8 31.2 23.9 22.5 26.0
HbA1c (%) 7.1 – 0.8 7.6 5.6 7.8 8.2 7.3 7.9 6.8 6.2 7.3 7.1
HbA1c (mmol/mol) 55.0 – 8.7 60 38 62 66 56 63 51 44 56 54
TDD (U) 43.8 – 17.9 29.7 36 38 49 52 44 90 29.4 36.2 33.5
Duration of diabetes (years) 18.0 – 5.7 18 9.5 17 12 13 16 21 28 24 22
Duration insulin pump (years) 6.9 – 2.4 4 5 11 5 5 8 8 9 9 5
Dinner size (g of carbohydrates) 57.0 – 16.3 60 40 50 60 60 90 60 30 70 50
Breakfast size (g of carbohydrates) 41.0 – 12 50 30 20 40 60 40 50 30 50 40
Open loop
Mean BG overnight period (mmol/L) 7.79 – 2.3 9.81 5.58 9.05 6.02 5.37 9.25 5.6 7.87 7.08 12.31
Time at glucose level (%) overnight period
< 3.9mmol/L 7.3 – 9.1 0 20 0 20 6.7 6.7 20 0 0 0
3.9–8mmol/L 49.7 – 32.6 3.3 80 6.7 60 93.3 60 70 50 66.7 6.7
8–10mmol/L 24.0 – 24.9 50 0 76.6 20 0 6.7 10 43.3 13.3 20
> 10mmol/L 19.0 – 24.4 46.7 0 16.7 0 0 26.6 0 6.67 20 73.3
Closed loop
Mean BG overnight period (mmol/L) 6.82 – 1.9 5.94 5.52 9.66 10.58 5.58 4.94 7.13 5.87 5.18 7.76
Time at glucose level (%) overnight period
< 3.9mmol/L 0.7 – 2.1 0 6.7 0 0 0 0 0 0 0 0
3.9–8mmol/L 79.0 – 28 100 93.3 13.3 53.3 100 93.3 70 100 96.7 70
8–10mmol/L 10.7 – 17.5 0 0 53.4 6.7 0 6.7 30 0 3.3 6.7
> 10mmol/L 9.6 – 16 0 0 33.3 40 0 0 0 0 0 23.3
BG, blood glucose; BMI, body mass index; F, female; HbA1c, hemoglobin A1c; M, male; TDD, total daily dose.
FIG. 1. Median and interquartile range of blood glucose (BG) values (YSI) during the overnight period. After 10 h of
predictive rule-based algorithm action a convergence between all subjects in a near-normoglycemic point was observed.
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Mean Low BG Index decreased during CL (2.18 vs. 1.09), as
did High BG Index (3.95 vs. 1.60). Reduction in the BG Risk
Index (6.13 to 2.70) achieved statistical significance (P < 0.05).
CGM glucose values in some patients showed an unexpected
extreme stability that was confirmed by the YSI measure-
ments: Patient 1 remained for 115min between 6.0 and
6.11mmol/L, Patient 4 had sensor glucose values between
5.66 and 5.77mmol/L for 125min, Patient 5 also remained for
205min with sensor glucose values between 5.11 and
5.44mmol/L, and Patient 9 had sensor values between 6.66
and 6.77mmol/L for 110min. This phenomenon was not
observed in any patient with OL.
Insulin doses
A comparison between insulin doses actually administered
(downloaded from the pump) and insulinmicrobolus proposed
by the algorithm revealed no omissions or discrepancies.
Total insulin dose using OL was similar to the insulin dose
given with CL (0.28 – 0.09 vs. 0.23 – 0.08 IU/kg), in which
144 boluses (minimum 0.05 units) were administered to each
patient.
Postprandial period (8 a.m.–10 a.m.)
In total, 41 – 12 g of carbohydrates was supplied for
breakfast. In CL conditions, a meal priming bolus was ad-
ministered 15min before ingestion (3.2 – 1.7 IU). In OL, pa-
tients decided the timing for the insulin bolus based on their
CGM and BG measurements. No statistical differences be-
tween CL and conventional insulin pump therapywere found
in the mean BG level during the postprandial period (OL vs.
CL, 8.7 – 3.1 vs. 8.3 – 2.3mmol/L), the percentage of time in
target (3.9–10.0mmol/L) (OL vs. CL, 58.3% [29.1–87.4%] vs.
50.0% [50–100%]), and the area under the curve of BG values
(OL vs. CL, 1,052.7– 347.5 vs. 1,028.7 – 312.8mmol/L$min).
Using the algorithm control, glycemic excursions seemed to
be symmetrical with amaximum around 90min after themeal
intake (Fig. 3). However, with the standard premeal bolus,
postprandial glycemic curves were more erratic, having os-
cillations and different peak times among patients.
Conclusions
This randomized crossover study has demonstrated that a
CL system with a pRBA achieves normoglycemia more than
95% of the time during the nocturnal period without in-
creasing the risk of hypoglycemia. Postprandial results,
although not inferior to those obtained with a standard
premeal bolus, did not avoid an excessive glycemic excur-
sion, at least in some patients. The percentage of time spent
in target range is higher in our study compared with other
CL studies. In fact, a very recently published multicenter
outpatient study in close supervision (hotel, guest house,
hybrid hospital-hotel) reported 72% of the overnight time
to be within 3.9–10mmol/L.24 Previous in-clinic CL trials
using controllers that imitate the reasoning of diabetes
caregivers15,25 have shown an increase in overnight glucose
stability. However, CL comparison was done with CGM and
not with venous glucose values.
In our study, reduction of hypoglycemia, measured as time
spent with a BG level <3.9mmol/L and as reduction in the
number of episodes under the same threshold, is significant
and better than that observed in other single-hormone CL
studies.8,9,11
Because the nocturnal period corresponds roughly with
one-third of the total lifetime, near-normalization of glucose
values during the night without increasing hypoglycemia risk
would have a worthwhile impact on the diabetes burden.
Although our postprandial results were not exceptionally
good, the use of the algorithm allows for a more predictable
glucose excursion with a maximum around 90min after
meal intake. Knowing this could be useful for future control
strategies.
The strategy used by our controller is different from the
methods used to build an artificial pancreas most widely re-
ported in the literature (model predictive control and pro-
portional integral derivative). However, solutions based on
rule-based approaches have also yielded improvement in
glycemic control,15 as confirmed by our experience with the
pRBA controller. Despite the increasing number of clinical
studies to test alternative control algorithms, it is unclear
whether any one system has more advantages than another.
Personalization in line with each patient’s characteristics is
an essential element to arrive at a successful algorithm.
Model-based algorithms appear to be the most widely ac-
cepted strategy, as they consider physiologic knowledge and
personal conditions by ad hoc adjustment of several param-
eters to each patient. Even so, setting a specific patient’s
model is quite a complex process. The pRBA algorithm is also
adjusted to each patient by using the previously prescribed
CSII therapy and personalized parameters, complemented by
a generic predictive neural network trained with a population
of T1DM patients, which makes generalization to a wider set
of patients easier.18 It requires no previous training with each
FIG. 2. Percentage of time in different blood glucose (BG)
ranges corresponding to the overnight period (10 p.m.–8
a.m.): open loop (white boxes) and closed loop (striped boxes).
*Difference statistically significant at P< 0.05. Black circles
correspond to outliers. Percentage of time in target was clearly
higher with closed loop. Percentage of time with BG values
<3.9mmol/L was significantly lower with closed loop.
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6
patient’s specific features. The idea of predicting either hy-
poglycemia or hyperglycemia episodes as a safety alternative
has been proposed previously.26 Our approach is not only to
take advantage of glucose prediction to estimate the future
rate of change in glucose levels, which was used by the pRBA
as a safety constraint, but also to determine the accepted range
in glucose stability.
As mentioned earlier, an unexpected degree of glucose
stability was observed under CL conditions.We hypothesized
that our algorithm proposing a microbolus every 5min,
mimicking the physiological pulsatile insulin secretion,27,28
could contribute to insulin action optimization and favor
stability. This pulsatile administration is different than the
strategy used in other CL studies,7–9,13,15,29 in which a change
in the insulin delivery rate is made so insulin is distributed
throughout the actuation period.
Our study has some limitations. The sample size is small,
although similar in number to other previously published CL
studies. However, because the entire study was carried out at
the same center, the risk of heterogeneity in procedures that
can occur in multicenter trials is reduced. Communication
between devices was done manually and could therefore be a
source of errors, but stringent measures were taken to mini-
mize the risk of error, and no omissions or discrepancies were
observed between insulin doses proposed by the algorithm
and those really administered. Two CGM devices were used:
one as a reference for the experiment, whereas the second was
kept as backup to be used in case of failure of the reference
sensor. An outpatient study should address the management
of the automatic detection of sensor failure. Future outpatient
studies would require CGM calibration equal to that achieved
by YSI to guarantee accuracy. The period between the
breakfast and the end of the trial was too short, and probably a
longer period of around 5–6 h would have clarified whether
the pRBA had any beneficial impact on the postprandial
glycemic control.
In conclusion, this study shows that the pRBA is a new,
more physiological, and highly precise controller that
achieves a significant increase in overnight normoglycemia
and glucose stability in patients with a previously acceptable
metabolic control.
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